Europeiska unionen -
svenska -
EMA (European Medicines Agency)
apixaban accord
accord healthcare s.l.u. - apixaban - venous thromboembolism; stroke; arthroplasty - antitrombotiska medel - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery. förebyggande av stroke och systemisk embolism hos vuxna patienter med icke-valvulär förmaksflimmer (nvaf), med en eller flera riskfaktorer, såsom tidigare stroke eller transitorisk ischemisk attack (tia), ålder ≥ 75 år, hypertoni, diabetes mellitus; symtomatisk hjärtsvikt (nyha klass ≥ ii). behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe hos vuxna (se avsnitt 4. 4 för hemodynamiskt instabila pe patienter). prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii). behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe hos vuxna (se avsnitt 4. 4 för hemodynamiskt instabila pe patienter).
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
rivaroxaban accord
accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotiska medel - förebyggande av venös tromboembolism (vte) hos vuxna patienter som genomgår elektiv höft- eller knäbytesoperation. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 for haemodynamically unstable pe patients. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 för hemodynamiskt instabila pe patienter). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 och 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
evrenzo
astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianemiska preparat - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiska medel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.